Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Shareholder Meeting (April 2023)

17 slides from Sernova Biotherapeutics's shareholder meeting presentation, Apr 27, 2023

  1. Slide 1: Advancing cell therapeutics to provide 'functional cures'

    Slide 1: Advancing cell therapeutics to provide 'functional cures'

    Advancing cell therapeutics to provide ‘functional cures’ Sernova Annual General Meeting April 27, 2023 1

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

  3. Slide 3: 2023 AGM Presentation Agenda

    Slide 3: 2023 AGM Presentation Agenda

    2023 AGM Presentation Agenda • Brief Update on Sernova’s type 1 diabetes (T1D) clinical program o Cohort 1 update o Cohort 2 enrolment update • Sernova rationale using islets as a ‘functional cure’ for TID as opposed to insulin injections • Sernova’s iPSC islet cluster technology being developed wit

  4. Slide 4: Sernova: Innovator and Leader

    Slide 4: Sernova: Innovator and Leader

    Sernova: Innovator and Leader Cell Therapeutics: Paradigm Shift for Superior Treatment of High-Maintenance, Lifelong Conditions • Sernova’s integrated Cell Pouch System™ provides the potential for a ‘functional cure’ for chronic medical conditions with multi-billion dollar market potential • Cell Po

  5. Slide 5: Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2

    Slide 5: Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2

    Phase 1/2 Study – Cohort 1 Informed / Guided to Cohort 2 Advancing With A Higher Capacity Cell Pouch Product • Cohort 1 (6 patients) o Patients demonstrated a clear safety profile for Cell Pouch System o Established threshold for islet dose and density optimization o Cohort 1 update coming at Americ

  6. Slide 6: The Advantages of Pancreatic Islets

    Slide 6: The Advantages of Pancreatic Islets

    The Advantages Of Pancreatic Islets Over ed ° Alpha Cells Beta Cells Insulin : : Injection Pancreatic Islets: The Complete Approach lets global regula\ Sernova’s Cell Pouch System™ Evotec is manufactur tic islet-ike clusters (ILCs) that mimic the funct n islets. Sernovas Cell Pouch, in combination w

  7. Slide 7: Sernova and Evotec's Cell Therapy Commercial Approach for Type 1 Diabetes

    Slide 7: Sernova and Evotec's Cell Therapy Commercial Approach for Type 1 Diabetes

    Sernova and Evotec’s Cell Therapy Commercial Approach for the Treatment of Type 1 Diabetes The Patient Experience The Evotec iPSC-Based Manufacturing Process The Evotec induced pluripotent stem cell (iPSC)-based manufacturing process allows for the 1 | Using Good Manufacturing Practices, the commerc

  8. Slide 8: In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell Pouch

    Slide 8: In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell Pouch

    In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell PouchTM Evotec International GmbH, IPITA workshop April 24/25, 2023

  9. Slide 9: iPSC-derived islet-like clusters (ILCs) with long-term antidiabetic efficacy

    Slide 9: iPSC-derived islet-like clusters (ILCs) with long-term antidiabetic efficacy

    iPSC-derived islet-like clusters (ILCs) with long-term antidiabetic efficacy Robust, durable normalization of glycemic control in diabetic mice Efficient normalization of random fed glucose Circulating hC-peptide by kidney capsule-implanted ILCs Evotec GMP manufacturing site near Modena/Italy • We h

  10. Slide 10: Combining high quality iPSC-derived ILCs with a clinically proven device

    Slide 10: Combining high quality iPSC-derived ILCs with a clinically proven device

    Combining high quality iPSC-derived ILCs with a clinically proven device Evotec ILCs with Sernova Cell PouchTM • The Sernova Cell PouchTM is a pre- implanted, vascularized device providing an optimal environment for therapeutic cell function1 − Accessible/retrievable implantation site • Sernova has

  11. Slide 11: Testing the ILC + Cell Pouch combination in diabetic mice

    Slide 11: Testing the ILC + Cell Pouch combination in diabetic mice

    Testing the ILC + Cell PouchTM combination in diabetic mice Sentinel-size Cell PouchTM in STZ-diabetic NSG mice with ILCs containing 1.7 x 106 beta cells Implant ILCs into Cell Pouch (1.7 x 106 β-cells) implant Cell PouchTM 1) hC- hC- end of inject peptide oGTT peptide oGTT exp./histology STZ 2 week

  12. Slide 12: Excellent anti-diabetic activity of ILCs in the Cell Pouch

    Slide 12: Excellent anti-diabetic activity of ILCs in the Cell Pouch

    Excellent anti-diabetic activity of ILCs in the Cell PouchTM Rapid normalization of glycemic control with human islet-like potency Efficient normalization of random fed glucose Robust circulating hC-peptide levels Efficient glucose mouse glucose setpoint clearance and no hypoglycemias in oGTT (8 wee

  13. Slide 13: High β-cell fraction and dense vascularization of ILCs in the Cell Pouch

    Slide 13: High β-cell fraction and dense vascularization of ILCs in the Cell Pouch

    High β-cell fraction and dense vascularization of ILCs in the Cell PouchTM Histological graft analysis – 32 weeks post-implantation INS • Abundant endocrine cells with high GCG beta cell fraction detectable SST DAPI • Alpha and delta cells are observed at lower frequencies INS CD31 DAPI INS • ILC ce

  14. Slide 14: Excellent anti-diabetic activity of an ILC/Cell Pouch combination

    Slide 14: Excellent anti-diabetic activity of an ILC/Cell Pouch combination

    Excellent anti-diabetic activity of an ILC/Cell PouchTM combination Summary • We have set up a scalable GMP manufacturing workflow from GMP iPS cells to ILCs, yielding a high beta cell fraction drug product − ILCs are cryopreserved at a late intermediate stage − Endocrine differentiation is complete

  15. Slide 15: Upcoming Catalysts

    Slide 15: Upcoming Catalysts

    a Sernova 4, oor Upcoming Catalysts

  16. Slide 16: Upcoming Catalysts

    Slide 16: Upcoming Catalysts

    Upcoming Catalysts Anticipated Milestones and Data 2023 • Immune protection update H1 2023 • US Phase 1/2 T1D second cohort patient enrollment update H1 2023 • US Phase 1/2 T1D first cohort clinical update Q2 2023 • US Phase 1/2 T1D second cohort clinical update Q4 2023 • FDA interactions regarding

  17. Slide 17: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH

    Slide 17: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH

    TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH Business Development Investor Relations Dr. Philip Toleikis Head Office Christopher Barnes VP, Investor Relations 1.519.858.5184 700 Collip Circle, Ste 114 philip.toleikis@sernova.com 1.519.902.7923 London, ON, Canada N6G 4X8 christopher.barnes@sernova.com Tel:

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks